Author:
Graham David Y.,Dore Maria Pina
Subject
Gastroenterology,Hepatology
Reference32 articles.
1. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: Pharmacokinetic and pharmacodynamic considerations;Echizen;Clin Pharmacokinet,2016
2. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases;Hori;J Pharmacol Exp Ther,2010
3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects;Sakurai;Clin Transl Gastroenterol,2015
4. Proton pump inhibitors;Fock;Clinical pharmacokinetics,2008
5. Vonoprazan: first global approval;Garnock-Jones;Drugs,2015
Cited by
86 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献